Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Zaltrap

Sanofi reception

Sanofi bolsters pipeline with $3.7bn deal for Principia Biopharma

French drugmaker will gain access to a portfolio of BTK inhibitors

Sanofi reception

Sanofi faces manslaughter allegations in France over Depakine deaths

Charges relate to deaths of four babies whose mothers took anti-epileptic drug during pregnancy

- PMLiVE

US secures 100 million doses of Sanofi/GSK’s COVID-19 vaccine

Both companies are also in talks with EU for access to candidate

- PMLiVE

UK government and GSK/Sanofi sign COVID-19 vaccine supply deal

UK adds to its arsenal of potential vaccine candidates

- PMLiVE

NICE recommends Astellas’ Xospata for NHS use

Cost-effectiveness watchdog backtracks on previous rejection

- PMLiVE

Britain closes in on £500m COVID-19 vaccine deal with Sanofi/GSK

Alleged deal could include agreement for 60 million doses

Sanofi reception

Sanofi doses first patient in global Kevzara COVID-19 trial

Sanofi is leading trials outside the US while Regeneron is leading US trials

- PMLiVE

In virtual meeting, CHMP backs Sanofi’s myeloma drug Sarclisa

Monthly meeting held remotely for the first time due to COVID-19 pandemic

- PMLiVE

NICE looks internally for new chief executive

Deputy chief exec Gillian Leng is set to take the helm

- PMLiVE

Sanofi, Regeneron launch trials of arthritis drug Kevzara for COVID-19

The interleukin-6 inhibitor will be evaluated in critically ill patients

Sanofi reception

FDA approves Sanofi’s key cancer drug Sarclisa for myeloma

First cancer drug wholly owned by company to be approved in past decade

- PMLiVE

Celgene’s Revlimid scores NICE approval in follicular lymphoma

New ‘chemotherapy-free’ treatment for patients with limited options

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links